Akcea Therapeut (NASDAQ:AKCA) Coverage Initiated by Analysts at BMO Capital Markets
AKCA has been the topic of a number of other reports. Cowen and Company initiated coverage on shares of Akcea Therapeut in a report on Tuesday. They set an “outperform” rating on the stock. Stifel Nicolaus initiated coverage on shares of Akcea Therapeut in a report on Tuesday. They set a “buy” rating and a $19.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Akcea Therapeut in a report on Tuesday. They set an “outperform” rating on the stock.
Akcea Therapeut (NASDAQ:AKCA) opened at 14.90 on Tuesday. Akcea Therapeut has a 12 month low of $8.10 and a 12 month high of $16.30. The firm’s 50-day moving average is $9.17 and its 200 day moving average is $9.17. The stock’s market capitalization is $956.55 million.
TRADEMARK VIOLATION NOTICE: “Akcea Therapeut (NASDAQ:AKCA) Coverage Initiated by Analysts at BMO Capital Markets” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/08/akcea-therapeut-nasdaqakca-coverage-initiated-by-analysts-at-bmo-capital-markets.html.
In other Akcea Therapeut news, major shareholder Ionis Pharmaceuticals Inc bought 3,125,000 shares of the company’s stock in a transaction on Wednesday, July 19th. The shares were bought at an average cost of $8.00 per share, with a total value of $25,000,000.00. Following the completion of the acquisition, the insider now owns 28,884,540 shares of the company’s stock, valued at $231,076,320. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
About Akcea Therapeut
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeut and related companies with MarketBeat.com's FREE daily email newsletter.